PlainPharmaWatch

CMS Open Payments · Program Year 2024

Novartis Gene Therapies, Inc. (fka Avexis, Inc.)

Novartis Gene Therapies, Inc. (fka Avexis, Inc.) reported $120,016.16 across General Payments, Research, and Ownership to 15 physicians and teaching hospitals across 39 transactions.

See the rankings → How this is sourced
$120.0K Below-median payer
All-tracks total
39 Below-median volume
Transactions
15 Below-median reach
Recipients
−$154.6K
General Payments vs PY2023

Novartis Gene Therapies, Inc. (fka Avexis, Inc.) reported $120,016.16 across all CMS Open Payments tracks (General + Research + Ownership) to 15 physicians and teaching hospitals in Program Year 2024 - ranking #1136 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $72,166.50, averaging $8.0K per recipient.

How Novartis Gene Therapies, Inc. (fka Avexis, Inc.)'s $120.0K all-tracks total breaks down

Novartis Gene Therapies, Inc. (fka Avexis, Inc.)'s payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

17/100

Total payments

F

11/100

Transaction volume

F

10/100

Physician reach

F

10/100

Payment type diversity

F

37/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer novartis-gene-therapies-inc-fka-avexis-inc Novartis Gene Therapies, Inc. (fka Avexis, Inc.)

$120.0K · #1136/1,925 · 0.0% industry · PY2024

  • TOT $120.0K
  • RANK #1136
  • SHARE 0.0%
  • TXN 39
  • RCP 15
  • CAT 3
  • GEN $72.2K
  • ΔGEN −$154.6K
  • TOP1 56.0%
  • PY 2024

Volume peers

Nearest volume peer: NuMED for Children, LLC ($120.0K)

Shalby Advanced Technologies…$120.5KCorMedix Inc.$120.2KAurobindo Pharma USA, Inc.$120.1KNovartis Gene Therapies, Inc…$120.0KNuMED for Children, LLC$120.0K
All-tracks payment totals near Novartis Gene Therapies, Inc. (fka Avexis, Inc.) (CMS Open Payments PY2024)

Novartis Gene Therapies, Inc. (fka Avexis, Inc.) sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Novartis Gene Therapies, Inc. (fka Avexis, Inc.)'s CMS-reported General Payments decreased by $154.6K (−68.2%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: NOVARTIS GENE THERAPIES, INC. (FKA AVEXIS, INC.)PY2023: NOVARTIS GENE THERAPIES, INC. (FKA AVEXIS, INC.)PY2024: Novartis Gene Therapies, Inc. (fka Avexis, Inc.). Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$226.8KPY2024$72.2K
PY2023
$226,815.35
PY2024
$72,166.50

What the Data Shows for Novartis Gene Therapies, Inc. (fka Avexis, Inc.)

Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Novartis Gene Therapies, Inc. (fka Avexis, Inc.), that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.

Of the 3 general-payment categories charted below, "Compensation for Services Other Than Consulting" is the largest at $69.5K across 3 transactions, 96.3% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Novartis Gene Therapies, Inc. (fka Avexis, Inc.) made 3 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $69.5K, 96.3% of General Payments.

How Novartis Gene Therapies, Inc. (fka Avexis, Inc.) divides its payments

Ranked by total dollars reported per category

1. Compensation for Services…$69.5K2. Consulting Fee$1.9K3. Food and Beverage$749.72
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $69.5K 3
Consulting Fee $1.9K 2
Food and Beverage $749.72 10

Recipient Concentration in General Payments

The five largest recipient relationships account for $71,581.83 (99.2%) of $72,166.50 in this company's General Payments records across 13 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Novartis Gene Therapies, Inc. (fka Avexis, Inc.)

The five named recipients with the highest reported General Payments from this company

Univ Of Mi Hospitals & Hlth …$40.4KRonald Reagan Ucla$29.1KJerry Mendell$1.4KSaunder Bernes$565.00Ana Tesi Rocha$165.05
  1. 1

    Univ Of Mi Hospitals & Hlth Ctrs

    $40,397.44 across 2 reported transactions

  2. 2

    Ronald Reagan Ucla

    $29,078.34 across 1 reported transactions

  3. 3

    Jerry Mendell

    $1,376.00 across 1 reported transactions

  4. 4

    Saunder Bernes

    $565.00 across 1 reported transactions

  5. 5

    Ana Tesi Rocha

    $165.05 across 2 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Novartis Gene Therapies, Inc. (fka Avexis, Inc.) ranks #1136 of 1,925 by total payments (bottom 41% by spend) but is notably more concentrated than that alone would suggest -- #391 of 1,838 by HHI (top 21% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.

00.30.50.81.14609.54672.847364799.34862.5Total payments ($M)Concentration (HHI, 0-10,000)
Novartis Gene Therapies, Inc. (fka Avexis, Inc.) (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Novartis Gene Therapies, Inc. (fka Avexis, Inc.)'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Novartis Gene Therapies, Inc. (fka Avexis, Inc.).

Topcon Corporation

HHI 4774

Optimotion Implants, LLC

HHI 4777

Ipsen Bioscience Inc.

HHI 4780

EMD Millipore Corporation

HHI 4713

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Novartis Gene Therapies, Inc. (fka Avexis, Inc.).

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Novartis Gene Therapies, Inc. (fka Avexis, Inc.) ranks #1136 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Novartis Gene Therapies, Inc. (fka Avexis, Inc.)'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.